José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
Children with recent-onset juvenile idiopathic arthritis (JIA) did not show signs of wrist damage over two years of treatment targeting inactive ... Read more
Using conventional treatment strategies is an effective approach in most children with juvenile arthritis (JIA) and is still recommended as a ... Read more
Long-term treatment with Actemra (tocilizumab) shows sustained safety and effectiveness in children with polyarticular juvenile idiopathic arthritis (pJIA), according to the ... Read more
Treatment of systemic juvenile idiopathic arthritis (sJIA) with either the approved therapy Actemra (tocilizumab) or Kineret (anakinra, not yet approved for sJIA) led to ... Read more
Tocilizumab, an approved therapy for children and adults with systemic juvenile idiopathic arthritis, is effective in real-life setting and shows evidence of ... Read more
Use of a psychotherapy method effectively reduces symptoms of methotrexate (MTX) intolerance in patients with juvenile idiopathic arthritis (JIA), according to ... Read more
U.S. demand for rheumatologists will greatly surpass the projected growth of the rheumatology workforce over the next 12 years, two studies ... Read more
Canadian government approval of Aristospan (triamcinolone hexacetonide) to treat juvenile arthritis reinforces the global expansion efforts of Germany’s Riemser Pharma, which recently ... Read more
Adalimumab improves the eye inflammation of children with early-onset juvenile idiopathic arthritis, a Phase 2/3 clinical trial shows. The study, published ... Read more
